This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SREBF1 | |
|---|---|
| Name | SREBF1 |
SREBF1 SREBF1 is a transcriptional regulator central to lipid homeostasis and cellular metabolism. It bridges membrane biology with nuclear transcriptional programs by responding to sterol status and growth cues, integrating signals that affect fatty acid synthesis and membrane biogenesis. The gene is conserved across mammals and has been studied in contexts ranging from endocrinology to oncology.
SREBF1 is a basic helix–loop–helix leucine zipper transcription factor first characterized in studies that linked sterol regulation to gene expression in hepatic and adipose tissues. Early descriptions connected its activity to work on cholesterol metabolism by groups studying statins, peroxisome proliferator-activated receptors, and insulin signaling in laboratories affiliated with institutions such as Harvard, Stanford, and the National Institutes of Health. Investigations into SREBF1 intersect with research on insulin resistance in centers like the Joslin Diabetes Center and with metabolic syndrome studies at the World Health Organization and the International Diabetes Federation.
The protein contains an N-terminal transcription factor domain with a basic helix–loop–helix leucine zipper motif, a membrane-spanning region, and a C-terminal regulatory domain. Alternative transcription start sites and differential splicing generate distinct isoforms that differ in transcriptional potency and tissue expression patterns, analogous to isoform diversity described for p53, BRCA1, and NF-κB family members in work from laboratories at Cold Spring Harbor Laboratory and the Salk Institute. Structural analyses have been informed by collaborations involving the European Molecular Biology Laboratory, the Max Planck Society, and cryo-EM groups at the Howard Hughes Medical Institute. Ortholog comparisons use sequence resources from EMBL-EBI, NCBI, and UniProt, and functional motifs are compared against databases curated by the Wellcome Sanger Institute and the Broad Institute.
SREBF1 controls transcription of enzymes involved in fatty acid and triglyceride synthesis through direct binding to sterol regulatory elements in promoters, a mechanism revealed alongside studies on HMG-CoA reductase, ATP-citrate lyase, and acetyl-CoA carboxylase by research teams at the University of California, San Francisco, Yale University, and Cambridge. Activation requires proteolytic cleavage and nuclear translocation, processes studied in cell systems developed in laboratories at Massachusetts Institute of Technology, Rockefeller University, and Kyoto University. The transcriptional program governed by SREBF1 overlaps with targets of CREB, FOXO1, PPARα, and ChREBP as mapped using technologies from Illumina, Agilent, and Thermo Fisher Scientific and analyzed with pipelines from the Broad Institute and EMBL-EBI.
SREBF1 activity is regulated by sterol-sensitive retention in the endoplasmic reticulum via interactions with SCAP and INSIG proteins; this regulatory axis was elucidated in studies at Johns Hopkins University and the University of Texas Southwestern Medical Center. Post-translational modifications including phosphorylation by kinases such as AKT, MAPK, and AMPK, as well as ubiquitination and sumoylation, modulate stability and activity, concepts paralleled in investigations of signaling by EGFR, mTOR, and GSK3 in labs at Memorial Sloan Kettering Cancer Center and the Dana-Farber Cancer Institute. Proteasomal degradation pathways involving ubiquitin ligases characterized at institutions like Cold Spring Harbor and the Max Planck Institute further influence SREBF1 turnover, and mass spectrometry mapping has been carried out using platforms at Rockefeller University and EMBL.
SREBF1 drives expression of lipogenic enzymes such as FASN, SCD1, and ACLY, coordinating de novo lipogenesis during fed states and in response to hormonal signals like insulin and growth factors studied at the Mayo Clinic, Karolinska Institute, and Imperial College London. Its role is central in hepatic steatosis models used by groups at the University of Cambridge and the University of California, San Diego, and in adipogenesis programs explored by teams at the University of Pennsylvania and the University of Michigan. Interactions with nutrient-sensing pathways involving mTORC1, AMPK, and insulin receptor signaling connect SREBF1 function to research on obesity and type 2 diabetes pursued by the International Association for the Study of Obesity and the American Diabetes Association.
Dysregulation of SREBF1 contributes to nonalcoholic fatty liver disease, insulin resistance, and dyslipidemia characterized in cohorts from the Framingham Heart Study, UK Biobank, and the Nurses' Health Study. Overactive pathways involving SREBF1 are implicated in cancer cell lipid metabolism in studies at Memorial Sloan Kettering, MD Anderson Cancer Center, and the National Cancer Institute, where altered lipogenesis supports tumor growth in malignancies such as hepatocellular carcinoma and breast cancer analyzed by investigators at the University of Texas MD Anderson and the Dana-Farber Cancer Institute. Genetic and pharmacologic modulation of SREBF1 intersects with clinical trials of lipid-lowering agents, metabolic modulators, and oncology therapeutics evaluated at the Food and Drug Administration and the European Medicines Agency.
Model systems include SREBF1 knockout and transgenic mice generated at institutions like The Jackson Laboratory and the Salk Institute, hepatocyte and adipocyte cell lines maintained in labs at EMBL and Cold Spring Harbor, and CRISPR/Cas9-edited human cell models developed at the Broad Institute and MIT. Assays for promoter binding use chromatin immunoprecipitation methods refined by the ENCODE Project and sequencing technologies from Illumina and Oxford Nanopore. Small-molecule inhibitors, RNAi libraries, and lipidomic platforms from companies such as Thermo Fisher Scientific and Agilent support functional studies, while bioinformatic resources at UCSC Genome Browser and Ensembl facilitate comparative analyses.
Category:Transcription factors